Clinical Trial Update: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial using the FES-PET imaging agent to determine estrogen receptor expression in epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Fluoroestradiol (FES) PET tracer (fluoroestradiol)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED